Mimrylo is the first subcutaneous hepcidin mimetic approved to control hematocrit levels and reduce phlebotomy burden in patients with polycythemia vera.

The researchers found that the adjusted mean percentage change in body weight at the 24-month follow-up was −3.40% for the Mediterranean-style intervention and −3.51% for the control intervention. The ...

A healthy lifestyle in early childhood is associated with a reduced risk for inflammatory bowel disease (IBD), according to a study published online August 24 i ...

The updated vaccines are expected to be available in pharmacies, hospitals, and clinics in the coming days. In May 2026, the FDA’s Vaccines and Related Biological Products Advisory Committee ...

Lisraya is the first oral dual TYK2/JAK1 inhibitor indicated for adults with dermatomyositis, demonstrating significant ...

HealthDay News — Baseline cortical atrophy measured within the early-onset Alzheimer disease (EOAD) signature, a set of predominantly parietotemporal regions showing greater atrophy in EOAD than in ...

Interim Phase 1b/2a trial data support the MKK4 inhibitor's potential to protect hepatocytes and accelerate liver regeneration following surgical resection.

Imaavy (nipocalimab-aahu) is the first FcRn blocker approved to treat warm autoimmune hemolytic anemia in patients aged 12 years and older.

HealthDay News — Paternal exposure to valproate during sperm development is not associated with neurodevelopmental disorders (NDDs) in offspring, according to a study published online August 19 in ...

The FDA has approved Tivicay PD dispersible tablets for combination HIV-1 treatment in full-term neonates weighing at least 2kg.